Oral small molecule GLP-1 receptor agonist
Aleniglipron 120 mg tablet once daily
ALENIG_PO_120MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -7.17 (-17.70 to 4.32) | 0.71 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.88 (-17.04 to -2.92) | 0.79 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.99 (-16.08 to -1.89) | 0.69 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.41 (0.28 to 7.51) | 0.44 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.91 (0.53 to 7.87) | 0.50 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.03 (2.08 to 8.34) | 0.44 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.22 (1.74 to 17.30) | 0.42 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.90 (0.37 to 2.21) | 0.78 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.15 (0.81 to 5.90) | 0.48 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.59 (0.25 to 10.99) | 0.56 |